[1]YANG L, XING G, WANG L, et al.Acute kidney injury in China:a cross-sectional survey[J].Lancet, 2015, 386 (10002) :1465-1471.
|
[2]KIM JJ, TSUKAMOTO MM, MATHUR AK, et al.Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis[J].Am J Gastroenterol, 2014, 109 (9) :1436-1442.
|
[3]GARCIA-TSAO G, PARIKH CR, VIOLA A.Acute kidney injury in cirrhosis[J].Hepatology, 2008, 48 (6) :2064-2077.
|
[4]HAO KY, YU YC.Several issues regarding evaluation of renal injury and renal insufficiency in patients with liver disease[J].J Clin Hepatol, 2016, 32 (8) :1483-1487. (in Chinese) 郝坤艳, 于乐成.肝病时肾损伤和肾功能不全评估的若干问题[J].临床肝胆病杂志, 2016, 32 (8) :1483-1487.
|
[5]ZANG H, LIU F, LIU H, et al.Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-onchronic liver failure (ACLF) of underlying cirrhosis[J].Hepato Int, 2016, 10 (5) :807-818.
|
[6]BITTENCOURT PL, FARIAS AQ, TERRA C.Renal failure in cirrhosis:emerging concepts[J].World J Hepatol, 2015, 7 (21) :2336-2343.
|
[7]ANGELI P, GINES P, WONG F, et al.Diagnosis and managemen of acute kidney injury in patients with cirrhosis:revised consensus recommendations of the International Club of Ascites[J].Gut, 2015, 62 (4) :968-974.
|
[8]BAGSHAW SM, UCHINO S, CRUZ D, et al.A comparison of observed versus estimated baseline creatinine for determination of RI-FLE class in patients with acute kidney injury[J].Nephrol Dial Transplant, 2009, 24 (9) :2739-2744.
|
[9]SHERMAN DS, FISH DN, TEITELBAUM I.Assessing renal function in cirrhotic patients:problems and pitfalls[J].Am J Kidney Dis, 2003, 41 (2) :269-278.
|
[10]SANYAL AJ, BOYER T, GARCIA-TSAO G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.
|
[11]SAGI SV, MITTAL S, KASTURI KS, et al.Terlipressin therapy for reversal of type 1 hepatorenal syndrome:a meta-analysis of randomized controlled trials[J].J Gastroenterol Hepatol, 2010, 25 (5) :880-885.
|
[12]BOYER TD, SANYAL AJ, WONG F, et al.Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1[J].Gastroenterology, 2016, 150 (7) :1579-1589.
|
[13]CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:a randomized controlled study[J].Hepatology, 2016, 63 (3) :983-992.
|
[14]SALERNO F, NAVICKIS RJ, WILKES MM.Albumin treatment regimen for type 1 hepatorenal syndrome:a dose-response meta-analysis[J].BMC Gastroenterol, 2015, 15:167.
|
[15]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
|
[16]EGEROD ISRAELSEN M, GLUUD LL, KRAG A.Acute kidney injury and hepatorenal syndrome in cirrhosis[J].J Gastroenterol Hepatol, 2015, 30 (2) :236-243.
|
[17]CAVALLIN M, KAMATH PS, MERLI M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:a randomized trial[J].Hepatology, 2015, 62 (2) :567-574.
|
[18]POMIER-LAYRARGUES G, PAQUIN SC, HASSOUN Z, et al.Octreotide in hepatorenal syndrome:a randomized, double-blind, placebo-controlled, crossover study[J].Hepatology, 2003, 38 (1) :238-243.
|
[19]SRIVASTAVA S, SHALIMAR, VISHNUBHATLA S, et al.Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome[J].J Clin Exp Hepatol, 2015, 5 (4) :276-285.
|
[20]GOYAL O, SIDHU SS, SEHGAL N, et al.Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1:a prospective, randomized trial[J].J Assoc Physicians India, 2016, 64 (9) :30-35.
|
[21]NASSAR JUNIOR AP, FARIAS AQ, D'ALBUQUERQUE LA, et al.Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome:a systematic review and meta-analysis[J].PLoSOne, 2014, 9 (9) :e107466.
|
[22]SHARMA P, KUMAR A, SHRAMA BC, et al.An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response[J].Am J Gastroenterol, 2008, 103 (7) :1689-1697.
|
[23]DUVOUX C, ZANDITENAS D, HZODE C, et al.Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome:a pilot study[J].Hepatology, 2002, 36 (2) :374-380.
|
[24]BRENSING KA, TEXTOR J, PERZ J, et al.Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome:a phase II study[J].Gut, 2000, 47 (2) :288-295.
|
[25]WONG F, PANTEA L, SNIDERMAN K.Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1hepatorenal syndrome[J].Hepatology, 2004, 40 (1) :55-64.
|
[26]BRENSING KA, TEXTOR J, STRUNK H, et al.Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome[J].Lancet, 1997, 349 (9053) :697-698.
|
[27]CHEN L, MEI Y, YANG YB, et al.Research advances in renal replacement therapy for hepatorenal sydrome[J].J Clin Hepatol, 2016, 32 (2) :605-608. (in Chinese) 陈丽, 梅永, 杨亦彬, 等.肾脏替代疗法治疗肝肾综合征的研究进展[J].临床肝胆病杂志, 2016, 32 (2) :605-608.
|
[28]MITZNER SR, STANGE J, KLAMMT S, et al.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS:results of a prospective, randomized, controlled clinical trial[J].Liver Transpl, 2000, 6 (3) :277-286.
|
[29]ZHANG Z, MADDUKURI G, JAIPAUL N, et al.Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin[J].JCrit Care, 2015, 30 (5) :969-974.
|
[30]WONG F.Treatment to improve acute kidney injury in cirrhosis[J].Curr Treat Options Gastroenterol, 2015, 13 (2) :235-248.
|
[31]BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J].Liver Transpl, 2011, 17 (11) :1328-1332.
|
[32]LEE JP, KWON HY, PARK JI, et al.Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation[J].Liver Transpl, 2012, 18 (10) :1237-1244.
|